Aplastic Anemia Market (Updated Version Available)

Key Market Overview:

Aplastic Anemia Market size was valued at USD 6,742.48 Million in 2022, registering a CAGR of 5.1% during the forecast period (2023-2030), and the market is projected to be worth USD 10,029.32 Million by 2030.

Aplastic anemia refers to a rare blood disorder that occurs when the stem cells in the patients bone marrow are unable to produce enough blood cells. The common symptoms of aplastic anemia include bruising, fatigue, shortness of breath, and others. The aplastic anemia drugs are effective for the treatment of the above symptoms. Furthermore, the patients may require a bone marrow transplant in severe cases.

For instance, according to the St. Jude Childrens Research Hospital based in the United States, approximately 300 to 600 new cases across all age groups in the United States. Thus, the rare nature of aplastic anemia is leading to the increasing research & development activities associated with the disease, which, in turn, is accelerating the growth of the market.

Von Willebrand Disease Market Report Coverage:

Report Attributes	Report Details
Study Timeline	2017-2030
Market Size in 2030 (USD Million)	10,029.32 Million
CAGR (2023-2030)	5.1%
Base Year	2022
By Treatment Type	Bone Marrow Transfusion/Stem Cell Therapy, Blood Transfusion, and Drug Therapy
By End User	Hospitals, Research Institutes, and Others
By Geography	Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia] Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey] North America [United States, Canada, Mexico] Middle East & Africa [GCC, North Africa, South Africa] South America [Brazil, Argentina, Columbia, Chile, Peru]
Key Players	Novartis Pharmaceuticals Corporation, Kyowa Kirin Co., Ltd., Foresee Pharmaceuticals, Cellenkos, Hemogenyx, Gamida Cell Ltd., GlaxoSmithKline Plc, Eisai Co. Ltd., Amyndas Pharmaceuticals S.A., and AbbVie Inc.

Request Sample

Market Dynamics:

Driver:

In hospitals, the utilization of aplastic anemia treatment enables vital treatment of aplastic anemia conditions to minimize the risk of serious infections. For instance, various hospitals in India such as Artemis Hospital, Indraprastha Apollo Hospitals, Max Super Specialty Hospital Saket, Apollo Hospital Chennai, and others are some of the prominent hospitals that are providing treatment for aplastic anemia. These players are actively investing to form strategic collaborations with major aplastic anemia players to increase the product offering in hospitals. Hence, the increasing deployment of aplastic anemia treatments in hospitals to reduce the risk of bleeding among patients is fostering market growth.

Restraint:

Aplastic anemia treatment has several side effects, including uncontrolled shivering, bleeding or bruising, nausea or vomiting, severe diarrhea, stomach cramps or constipation, and others. For instance, according to Leukaemia Foundation, aplastic anemia can affect the bone marrows ability to produce an adequate number of blood cells. In addition, aplastic anemia can also lead to coughing or shortness of breath, rash, reddening of the skin, and itching, among others. Thus, the several side effects associated with aplastic anemia treatment are a major concern for patients and healthcare providers and can limit adoption. For this reason, adverse side effects associated with Aplastic anemia treatment are hampering the demand of the market.

Opportunities:

The increasing partnerships between leading players dealing in aplastic anemia treatment, investment in research & development activities, and others are some of the prominent factors prompting the global aplastic anemia treatment manufacturers to develop a new range of treatments. This factor is leading to the increasing pipeline for the treatment of aplastic anemia treatment. For instance, Gamida Cell, a leading pharmaceutical manufacturer in Israel is developing OMIDUBICEL, a therapy for the treatment of severe aplastic anemia. Thus, the increasing pipeline for the treatment of aplastic anemia will create a potential growth opportunity for the market at the global level.

Market Segmentation:



By Treatment Type

The treatment type segment is classified into bone marrow transfusion/stem cell therapy, blood transfusion, and drug therapy. In 2022, the drug therapy segment accounted for the highest market share in the Aplastic Anemia market. Drug therapies such as cyclosporine (Neoral, Gengraf, and Sandimmune), anti-thymocyte globulin, and others are efficient for the treatment of aplastic anemia to minimize morbidity and prevent complications such as infections, heart problems, and bleeding, among others. Several drug therapy for the treatment of aplastic anemia is in the clinical trial phase. For instance, Campath is conducting clinical trials for Alemtuzumab, a drug for the treatment of aplastic anemia. Thus, the ongoing clinical trials associated with the drug therapy for the treatment of aplastic anemia will create a lucrative growth opportunity for the aplastic anemia market during the projected forecast period.

However, bone marrow transfusion/stem cell therapy is expected to grow at the fastest CAGR during the forecast period due to the rising research and development activities for the commercialization of various marrow transfusion/stem cell therapies for the efficient treatment of aplastic anemia.

By End User

The end user segment is categorized into hospitals, research institutes, and others. In 2022, the hospitals segment accounted for the highest market share in the aplastic anemia market. The hospital deploys various aplastic anemia treatments to suppress the activity of immune cells, which may pose damage the patients bone marrow. This helps the bone marrow to recover and produce new blood cells. The hospitals provide various treatment programs for aplastic anemia treatments, which is accelerating the treatment rate of aplastic anemia treatments.

For instance, Childrens Wisconsin Hospital, based in the United States has launched an Aplastic Anemia Program. The hospital is providing various treatments, including diagnosis, bone marrow transplant, and other treatments to treat aplastic anemia among children. Thus, the increasing programs for the treatment of aplastic anemia are boosting the growth of the market.

However, the research institutes segment is expected to be the fastest-growing segment over the forecast period owing to the increasing adoption of a new range of therapies.

By Region:

By region, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. In 2022, North Ameirca accounted for the highest market share in the Aplastic Anemia market due to the increasing investment in research and development activities for aplastic anemia treatments.

For instance, in 2021-2022, the Aplastic Anemia & Myelodysplasia Association of Canada (AAMAC) continued to provide funds for research focusing on bone marrow failure diseases. These researches included the Canadian Aplastic Anemia and Myelodysplastic Syndrome Study and single-cell profiling of blood hematopoietic stem cells for pediatric aplastic anemia treatment. The prime focus of this research is to develop novel treatments based on stem cells for the treatment of aplastic anemia. Thus, the increasing research and development activities in the North America region for the treatment of aplastic anemia are accelerating the growth of the market.



Nevertheless, Asia Pacific is expected to be the fastest-growing region over the forecast period due to the presence of major players in the market, the development of new aplastic anemia treatments, and others.

Aplastic Anemia Market Competitive Landscape:

The aplastic anemia market is highly competitive, with several large players and numerous small and medium-sized enterprises. These companies have strong research and development capabilities and a strong presence in the market through their extensive product portfolios and distribution networks. The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships. The key players in the market include-

• Novartis Pharmaceuticals Corporation
• Kyowa Kirin Co., Ltd.
• Foresee Pharmaceuticals
• Cellenkos
• Hemogenyx
• Gamida Cell Ltd.
• GSK Plc
• Eisai Co. Ltd.
• Amyndas Pharmaceuticals S.A.
• AbbVie Inc.

Recent Developments

In August 2021, GSK Plc, a leading manufacturer of pharmaceuticals in the United Kingdom, received FDA approval for JEMPERLI (dostarlimab-gxly). This drug can be utilized for the treatment of aplastic anemia.